PX1 Research provides standardized, analytical-grade Tesamorelin / Ipamorelin peptide blend 7mg formulated strictly for laboratory evaluation and in vitro research applications. Engineered to facilitate dual-pathway somatotropic axis investigation, this research compound undergoes comprehensive third-party testing to ensure verified identity and lot-to-lot consistency.
PX1 Research provides standardized, analytical-grade Tesamorelin / Ipamorelin peptide blend 7mg formulated strictly for laboratory evaluation and in vitro research applications. Engineered to facilitate dual-pathway somatotropic axis investigation, this research compound undergoes comprehensive third-party testing to ensure verified identity and lot-to-lot consistency.
Investigators seeking to buy Tesamorelin / Ipamorelin peptide blend 7mg require analytical-grade materials engineered specifically for standardized laboratory research. This dual growth hormone secretagogue blend combines a GHRH analog with a selective GHRP, providing researchers a calibrated compound verified by HPLC and MS to examine somatotropic axis modulation in preclinical assays.
When purchasing complex dual-peptide formulations for experimental protocols, verifying chemical integrity and exact stoichiometry is critical. PX1 Research supplies high-purity Tesamorelin / Ipamorelin blend 7mg specifically validated for in vitro assay systems, receptor binding studies, and cellular signaling research.
All materials distributed by PX1 Research are manufactured in US-based, GMP-compliant facilities and undergo full analytical verification. Each vial is accompanied by a lot-specific Certificate of Analysis (COA) detailing purity, mass confirmation, and safety parameters tailored to institutional research standards.
The Tesamorelin / Ipamorelin combination represents a dual-class research tool designed to activate two distinct pathways responsible for endogenous growth hormone (GH) transcription and exocytosis. In preclinical models, simultaneous stimulation of the Growth Hormone-Releasing Hormone Receptor (GHRH-R) and the Ghrelin/Growth Hormone Secretagogue Receptor (GHS-R1a) produces a potent, synergistic release of GH that exceeds the additive effects of either peptide evaluated independently.
Tesamorelin functions as a stabilized synthetic N-terminal modified analog of human GHRH. It binds specifically to the GHRH receptor on pituitary somatotropes, stimulating adenylate cyclase and increasing intracellular cyclic adenosine monophosphate (cAMP). This signaling cascade upregulates GH gene transcription and primes somatotropes for hormone release.
Concurrently, Ipamorelin operates as a selective agonist at the GHS-R1a receptor. Activation of this G-protein coupled receptor triggers intracellular calcium mobilization via the inositol trisphosphate (IP3) pathway. When introduced alongside GHRH activation, calcium influx triggers the fusion of pre-stored GH vesicles with the cell membrane, resulting in robust, physiological pulsatile GH secretion in cell cultures and animal models.
Tesamorelin (trans-3-hexenoyl HGHRH) is a 44-amino acid peptide incorporating a hexenoyl group attached to the N-terminal tyrosine residue. This structural modification enhances enzymatic stability against dipeptidyl peptidase-4 (DPP-IV) cleavage, extending its biological half-life in experimental media compared to native GHRH(1-44)-NH2.
In analytical literature, Tesamorelin research highlights its high specificity for the pituitary GHRH-R. Preclinical trials demonstrate that Tesamorelin stimulation leads to downstream activation of insulin-like growth factor 1 (IGF-1) expression in hepatic tissue without disrupting peripheral glucose homeostasis or inducing non-target trophic axis cascades.
Cellular assays show that Tesamorelin selective signaling preserves the ultra-short feedback loop governed by somatostatin. This regulatory feedback mechanism ensures that GH release patterns remain pulsatile rather than tonic, providing a natural research baseline for studying physiological endocrine dynamics.
Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. Recognized for extreme receptor selectivity, it is classified among the most refined growth hormone secretagogues studied in modern neuroendocrinology.
Unlike earlier ghrelin mimetics, Ipamorelin research confirms that its interaction with GHS-R1a does not stimulate secondary stress or appetite pathways. In vitro binding studies show negligible affinity for ACTH, cortisol, prolactin, or aldosterone receptors, allowing researchers to isolate GH-mediated biochemical effects without confounding off-target hormone spikes.
This high degree of receptor specificity makes Ipamorelin an ideal candidate for baseline comparative studies examining lipid oxidation, nitrogen retention, and cellular repair processes in animal tissues.
Published preclinical literature demonstrates that combining a GHRH agonist with a GHS-R agonist produces a synergistic amplification of growth hormone secretion. Rodent models exposed to dual-agonist preparations show significantly higher plasma GH peak amplitudes compared to subjects administered isolated compounds.
Crucially, preclinical evidence indicates that this dual-pathway activation preserves natural pulsatile secretion patterns. Because somatostatin inhibitory tones continue to regulate receptor sensitivity between pulses, somatotroph fatigue and receptor desensitization are minimized in long-term observational models.
Furthermore, in vitro assays confirm that the Tesamorelin / Ipamorelin combination maintains absolute selectivity. Measured plasma concentrations of adrenocorticotropic hormone (ACTH), cortisol, and prolactin remain within baseline physiological limits, reinforcing the utility of this blend in precise endocrine research. For broader context on secretagogue mechanics, visit the PX1 research library hub.
When evaluating GH secretagogues for experimental frameworks, researchers frequently contrast the Tesamorelin / Ipamorelin blend with alternative signaling agents. Understanding structural and functional distinctions is vital for selecting appropriate research compounds.
Compared to CJC-1295 No DAC, Tesamorelin exhibits distinct binding kinetics and an N-terminal modification engineered for enhanced GHRH-R binding affinity. While Sermorelin represents a truncated 29-amino-acid GHRH fragment with a short half-life, Tesamorelin provides superior metabolic stability in enzymatic environments.
When evaluating the secretagogue component against older agents such as GHRP-6, Ipamorelin demonstrates superior selectivity. GHRP-6 frequently induces significant elevations in serum cortisol and prolactin alongside intense ghrelin-mediated appetite stimulation in preclinical subjects. In contrast, Ipamorelin operates without triggering these non-target endocrine disruptions. Explore our complete line of research peptides to compare molecular configurations.
To preserve chemical integrity and prevent degradation, lyophilized Tesamorelin / Ipamorelin blend 7mg vials must be handled in accordance with standard aseptic laboratory protocols.
Lyophilized vials should be stored at -20°C for long-term stability. Exposure to light, moisture, and elevated ambient temperatures should be minimized. Prior to reconstitution, allow the vial to reach room temperature to prevent condensation within the matrix.
Reconstitution should be performed using sterile bacteriostatic water or laboratory-grade diluents. Gently direct the diluent down the glass wall of the vial rather than splashing directly onto the lyophilized cake. Allow the powder to dissolve passively or gently swirl the vial; never shake or introduce violent agitation, as shear forces can disrupt delicate peptide tertiary structures. Once reconstituted, solutions should be kept refrigerated at 2°C to 8°C and evaluated within established stability windows.
PX1 Research enforces strict quality control measures to ensure that every lot of Tesamorelin / Ipamorelin blend 7mg meets rigorous academic and industrial research criteria. Every production batch is synthesized in US-based, GMP-compliant facilities under sterile laboratory environments.
Chemical purity is validated using High-Performance Liquid Chromatography (RP-HPLC) to confirm structural homogeneous purity of ≥99%. Mass Spectrometry (MS) analysis is performed simultaneously to verify exact molecular weight and chemical composition, ruling out truncated peptides or residual synthesis artifacts.
In addition, PX1 Research subjects all finished lots to chromogenic LAL endotoxin testing to guarantee safety standards for cellular assays. Independent ISO 17025 accredited laboratories perform these analytical audits, and lot-specific Certificates of Analysis (COAs) are accessible for complete verification prior to purchase. Orders dispatch directly from our facilities in California and Arizona to preserve product integrity.
PX1 Research supports university laboratories, biotechnology enterprises, and institutional research programs requiring standardized supply chains for long-term investigative projects.
Through our wholesale procurement program, institutional partners gain access to bulk lot reservation, customized analytical testing, and dedicated account management. This infrastructure ensures consistent batch-to-batch reproducibility across longitudinal study phases while maintaining strict compliance with research-use specifications.
What is the total mass and composition of the Tesamorelin / Ipamorelin 7mg blend?
The vial contains a total lyophilized mass of 7mg, consisting of a precise ratio of analytical-grade Tesamorelin and Ipamorelin formulated specifically for dual-receptor preclinical research.
Why are Tesamorelin and Ipamorelin combined in research protocols?
Combining Tesamorelin (a GHRH analog) with Ipamorelin (a selective GHRP) allows researchers to study dual-pathway synergistic GH release, target both GHRH-R and GHS-R1a receptors simultaneously, and achieve higher baseline GH secretion without elevating cortisol or prolactin.
How is the purity of the 7mg blend verified by PX1 Research?
Each batch undergoes Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity assessment (≥99%) and Mass Spectrometry (MS) to confirm molecular weight. Every lot is also tested for endotoxin content via ISO 17025 accredited labs.
Does Ipamorelin elevate stress hormones or prolactin in preclinical models?
No. Preclinical literature demonstrates that Ipamorelin is highly selective for the GHS-R1a receptor and does not induce statistically significant elevations in ACTH, cortisol, or prolactin levels.
What solvent should be used to reconstitute the lyophilized blend?
Reconstitution for in vitro laboratory applications is typically conducted using sterile bacteriostatic water or sterile standard saline, depending on the requirements of the specific assay protocol.
How should the Tesamorelin / Ipamorelin blend be stored upon delivery?
Lyophilized powder should be stored at -20°C in a dry, dark environment. Reconstituted liquid solutions must be kept refrigerated at 2°C to 8°C and utilized within controlled experimental timelines.
What is the difference between Tesamorelin and CJC-1295?
Tesamorelin is a 44-amino-acid GHRH analog featuring a trans-3-hexenoyl modification at the N-terminus, specifically optimized for GHRH-R binding. CJC-1295 is a modified 29-amino-acid GHRH peptide designed with alternative structural alterations.
Can this compound be purchased for clinical or human use?
No. All products sold by PX1 Research, including the Tesamorelin / Ipamorelin blend 7mg, are strictly for laboratory research, in vitro assays, and preclinical experimental applications. They are explicitly not for human consumption, medical treatment, or clinical use.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.